Community pharmacists will not be selling the controversial Plan B emergency contraceptive OTCat least not this year. If the drug ever does win approval for nonprescription status, pharmacists may be called on to check the identity of purchasers.
Despite pressure from pro-choice groups to make the so-called "morningafter pill" available to women without a prescription, FDA officials raised concerns about the possible use of such a product by adolescent girls. In issuing a "Not Approvable" letter to Plan B sponsor Barr Laboratories, the FDA said that the company needs to conduct more research on the use of that product by girls younger than 16. "The sponsor's application contained no data on subjects under 14 years of age and very limited data on adolescents 14 to 16 years old," the agency letter said.
The FDA letter also said that Barr's application failed to include "adequate data to support use of Plan B by young adolescent women without the intervention of a physician."
The manufacturer is working to address the FDA's concerns. It is expected to issue a new proposal under which the drug would be sold OTC to women 16 and older, but by prescription only to those under 16.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs